| # | Drug | Count |
|---|---|---|
| 0 | LAMIVUDINE | 34 |
| 1 | LAMIVUDINE ORAL | 28 |
| 2 | PREDNISONE | 23 |
| 3 | DALFAMPRIDINE | 22 |
| 4 | EFAVIRENZ | 18 |
| 5 | OCRELIZUMAB | 18 |
| 6 | ZIDOVUDINE | 15 |
| 7 | IMATINIB | 14 |
| 8 | IMATINIB MESYLATE | 14 |
| 9 | NATALIZUMAB | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FOSTEMSAVIR TROMETHAMINE | 2 | 0.0082 |
| 1 | SULFACETAMIDE SODIUM | 1 | 0.0020 |
| 2 | EQUINE THYMOCYTE IMMUNE GLOBULIN | 2 | 0.0019 |
| 3 | IBALIZUMAB | 1 | 0.0019 |
| 4 | EFAVIRENZ | 18 | 0.0016 |
| 5 | ZIDOVUDINE | 15 | 0.0014 |
| 6 | CEFOTAXIME INJECTION | 6 | 0.0014 |
| 7 | LAMIVUDINE | 34 | 0.0013 |
| 8 | RILPIVIRINE | 8 | 0.0011 |
| 9 | ESTRIOL | 2 | 0.0011 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 1 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 25 | 0.0010 |
| 2 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 39 | 0.0008 |
| 3 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 69 | 0.0006 |
| 4 | Lipid-based Polyene Antifungal [EPC] | 7 | 0.0005 |
| 5 | Protease Inhibitor [EPC] | 20 | 0.0004 |
| 6 | CCR5 Co-receptor Antagonist [EPC] | 1 | 0.0004 |
| 7 | Cytochrome P450 3A Inhibitor [EPC] | 23 | 0.0004 |
| 8 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 8 | 0.0004 |
| 9 | Anthelmintic [EPC] | 1 | 0.0003 |